CD4 and Patent ductus arteriosus: The anti-human Gal-9 ab (1G3) was tested in a K-rasLSL.G12D/+;Pdx-1-Cre (KC) mouse of PDA where it reduced Treg, and increased CD4+ T cell, tumor infiltration and suppressed PDA progression [227].